6 indications × 50 states · 300 coverage permutations, all verified

Will my state Medicaid pay for a GLP-1 — on weight loss, T2D, MASH, OSA, pediatric or CV?

Pick your state and the indication you're asking about. The pre-screener returns the coverage status, the verbatim primary-source quote, the prior-authorization mechanics, the appeals pathway, the pharmacy-benefit manager (PBM), the managed-care structure, and a direct link to the full state research article. Every state row carries a verified-date badge showing when our editorial team last confirmed the data against the state Medicaid agency's primary source.

How to read the verified-date badge: any badge older than 90 days warrants a fresh confirmation with your state Medicaid program — Preferred Drug List (PDL) updates, State Plan Amendment (SPA) carve-ins/carve-outs, and PBM contract changes can flip a coverage status mid-year. Use the linked state article for the deeper PA-form, fibrosis-stage, BMI-threshold, and AHI-threshold detail.

Read this as a lookup of what is recorded, not a prediction of what your plan will do

This tool surfaces verified state-Medicaid coverage data; it is NOT medical, legal, or benefits advice. Individual coverage decisions depend on your specific eligibility category, managed-care plan assignment, comorbidities, and prior treatment history. Confirm directly with your state Medicaid program or your managed-care plan's member services line before assuming coverage. Prior-authorization criteria, BMI thresholds, and fibrosis-stage requirements can change without notice between editorial reviews.

50-state coverage overview (chronic weight management)

Derived directly from src/data/state-medicaid-coverage.json — every build recomputes the counter cards below straight from that data file. They are there to give you the national shape before you go looking at one state.

states cover obesity indication

Contrave, Saxenda, Zepbound or Wegovy sitting on the Medicaid PDL for chronic weight management, behind PA criteria

states facing sunset proposals

Coverage announced to end on a specific future date (MassHealth, Rhode Island, Utah)

states dropped coverage 2025–2026

South Carolina, Pennsylvania, New Hampshire and California Medi-Cal Rx — each denying from its own stated cutoff date

categorical-exclusion states

No chronic-weight-management coverage on Medicaid PDL; CV / OSA / MASH carve-outs may still apply

Look up your state and indication

Select your state and the indication you're asking about. The tool returns the verified coverage status, verbatim primary-source quote, PA form / fax / phone, appeals pathway, PBM, and a link to the full state research brief.

Your state

Indication

Choose a state above and you get its verified GLP-1 coverage data, how PA works there, and the primary-source quote word for word.

How to read the coverage status

Covered with PA — On the state Medicaid Preferred Drug List (PDL) for this indication. The prescriber must submit a prior-authorization request documenting BMI, comorbidities, and (for OSA / MASH / pediatric) the indication-specific clinical criteria.
Covered (sunset pending) — Currently covered, but the state Medicaid agency has announced an end date. PAs filed before the sunset date may still pay through the announced cutoff; new starts may be denied.
Carve-out only (PA required) — Not covered for chronic weight management as a primary indication, but covered for a specific carve-out (e.g., cardiovascular risk reduction with established CVD, or OSA with apnea-hypopnea index above the state threshold). PA criteria are narrower and indication-specific.
Not covered — this indication is off the state Medicaid PDL. That leaves cash, a manufacturer self-pay program, or a telehealth cash-pay route. Note that a state excluding chronic weight management categorically may still cover the MASH, OSA or CV carve-outs — the other tabs will tell you.
Dropped — coverage for this indication existed and the state Medicaid agency has since ended it. Every PA issued before then expires on the stated cutoff date.
Unverified — Our editorial team has not yet confirmed coverage for this specific indication against the state Medicaid agency's primary source. Confirm with your prescriber or the state Medicaid PBM before assuming coverage.

How this data is verified

The 50-state coverage dataset is backfilled from our state-Medicaid research series, where every state brief anchors on the state Medicaid agency's published Preferred Drug List (PDL), State Plan Amendments (SPAs), PA criteria documents, and managed-care PBM formularies. For broader context the dataset also references the Kaiser Family Foundation January 16, 2026 issue brief (“Medicaid Coverage of and Spending on GLP-1s”) and the Stateline April 30, 2025 reporting on state sunset proposals. Every state row carries a verified-date badge in lastVerified ISO format; click through to the linked state article for the deeper editorial review.

What this tool is NOT

This tool is a data lookup, not a coverage predictor. It will not tell you whether your specific prior-authorization request will be approved — that depends on your individual eligibility category, managed-care plan assignment, BMI, comorbidities, fibrosis stage (for MASH), apnea-hypopnea index (for OSA), prior weight-management history, and the clinical judgment of the state Medicaid medical director or PBM reviewer. Always confirm coverage directly with your state Medicaid program before assuming a result. Coverage policies can change mid-year via PDL updates, SPA filings, or PBM contract renegotiations.

References

1.Kaiser Family Foundation (Williams E, Hinton E, Rudowitz R). Medicaid Coverage of and Spending on GLP-1s — Issue Brief. KFF. 2026. https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/
2.Stateline (Vestal C). More states are dropping Medicaid coverage of pricey weight-loss drugs. Stateline. 2025. https://stateline.org/2025/04/30/more-states-are-dropping-medicaid-coverage-of-pricey-weight-loss-drugs/
3.healthinsurance.org. Medicaid eligibility and enrollment — state expansion tracker. healthinsurance.org. 2026. https://www.healthinsurance.org/medicaid/
4.Centers for Medicare & Medicaid Services. Medicaid Drug Rebate Program — covered outpatient drugs and State Plan Amendment (SPA) tracker. Medicaid.gov. 2026. https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html
5.GLP Watchdog Editorial Team. 50-state Medicaid GLP-1 coverage and prior-authorization pathway series (50 state research briefs). GLP Watchdog. 2026. https://glpwatchdog.org/states

Important disclaimer

This tool is for informational and educational use only and does not constitute medical, legal, or benefits advice. State Medicaid coverage information is sourced from publicly published PDLs, SPAs, and PA criteria; it is not authoritative and may not reflect last-minute policy changes. GLP Watchdog is not affiliated with any state Medicaid agency. Always verify coverage with your state Medicaid program, your managed-care plan's member services line, or your prescriber before making any treatment decisions. For appeals timelines and procedures, consult the state regulation cited in your specific state row.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.8